Core Viewpoint - Baosai Tu-B (02315) has seen a significant stock price increase of over 5%, currently trading at HKD 47.96, with a transaction volume of HKD 69.87 million [1] Financial Performance - The company forecasts its 2025 annual revenue to be approximately HKD 1.369 billion to HKD 1.389 billion, representing an increase of HKD 389 million to HKD 408 million compared to the previous year, with a year-on-year growth rate of 39.61% to 41.65% [1] - The expected net profit attributable to shareholders is projected to be around HKD 162 million to HKD 182 million, an increase of HKD 129 million to HKD 149 million from the previous year, indicating a substantial year-on-year growth of 384.26% to 443.88% [1] Market Insights - Guolian Minsheng Securities believes that the high demand for innovative animal models and preclinical CRO services is driving significant revenue growth [1] - The company has established partnerships with several leading domestic and international pharmaceutical companies since 2025, and multiple pipelines have received IND approvals, which are expected to generate milestone payments and further enhance growth potential [1]